Non-small cell lung cancer Trials in Lausanne, Switzerland
Conditions / Non-small cell lung cancer / Lausanne, Switzerland
Non-small cell lung cancer has been the subject of sustained clinical investigation across multiple research sites.
16 total trials for this combination
Showing top 10 of 16 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06561386 | A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% | RECRUITING | — |
| NCT06562192 | Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers | RECRUITING | — |
| NCT03645928 | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | RECRUITING | PHASE2 |
| NCT05013099 | Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05211895 | A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC | RECRUITING | — |
| NCT02477826 | An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) | COMPLETED | PHASE3 |
| NCT02147990 | Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer | TERMINATED | PHASE2 |
| NCT02031458 | A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | COMPLETED | PHASE2 |
| NCT06312137 | A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) | RECRUITING | — |
| NCT02075840 | A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants | COMPLETED | PHASE3 |